BioMarin Pharmaceutical Inc. Common Stock BMRN
i
Market dataready · fetched 2026-11-13T02:09:56.584Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T21:00:03.807260001Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-13T02:09:56.145814+00:00
BioMarin Pharmaceutical Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 50.97 | 93.1% | 11.7% | |||
| 25Δ | 59.29 | 41.6% | 5.6% | 52.39 | 88.3% | 9.7% |
| 30Δ | 58.82 | 43.3% | 5.1% | 55.33 | 34.3% | 3.5% |
| 35Δ | 58.35 | 45.0% | 4.6% | 55.72 | 35.0% | 3.2% |
| 40Δ | 57.88 | 46.7% | 4.1% | 56.10 | 35.7% | 2.8% |
| 45Δ | 57.39 | 48.9% | 3.6% | 56.49 | 36.4% | 2.5% |
| 50Δ | 56.78 | 53.0% | 3.3% | 56.88 | 37.1% | 2.1% |
| 55Δ | 56.17 | 57.1% | 3.0% | 57.26 | 37.8% | 1.8% |
| 60Δ | 55.56 | 61.1% | 2.8% | 58.00 | 39.4% | 1.5% |
| 65Δ | 54.94 | 64.8% | 2.5% | 59.28 | 42.3% | 1.3% |
| 70Δ | 54.19 | 64.0% | 2.0% | 60.57 | 45.3% | 1.1% |
| 75Δ | 53.45 | 63.2% | 1.6% | 61.85 | 48.2% | 0.9% |
| 80Δ | 52.71 | 62.3% | 1.2% | 63.14 | 51.1% | 0.7% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 50.97
- IV
- 93.1%
- B/E move
- 11.7%
25Δ
- Pseudo strike
- 59.29
- IV
- 41.6%
- B/E move
- 5.6%
- Pseudo strike
- 52.39
- IV
- 88.3%
- B/E move
- 9.7%
30Δ
- Pseudo strike
- 58.82
- IV
- 43.3%
- B/E move
- 5.1%
- Pseudo strike
- 55.33
- IV
- 34.3%
- B/E move
- 3.5%
35Δ
- Pseudo strike
- 58.35
- IV
- 45.0%
- B/E move
- 4.6%
- Pseudo strike
- 55.72
- IV
- 35.0%
- B/E move
- 3.2%
40Δ
- Pseudo strike
- 57.88
- IV
- 46.7%
- B/E move
- 4.1%
- Pseudo strike
- 56.10
- IV
- 35.7%
- B/E move
- 2.8%
45Δ
- Pseudo strike
- 57.39
- IV
- 48.9%
- B/E move
- 3.6%
- Pseudo strike
- 56.49
- IV
- 36.4%
- B/E move
- 2.5%
50Δ
- Pseudo strike
- 56.78
- IV
- 53.0%
- B/E move
- 3.3%
- Pseudo strike
- 56.88
- IV
- 37.1%
- B/E move
- 2.1%
55Δ
- Pseudo strike
- 56.17
- IV
- 57.1%
- B/E move
- 3.0%
- Pseudo strike
- 57.26
- IV
- 37.8%
- B/E move
- 1.8%
60Δ
- Pseudo strike
- 55.56
- IV
- 61.1%
- B/E move
- 2.8%
- Pseudo strike
- 58.00
- IV
- 39.4%
- B/E move
- 1.5%
65Δ
- Pseudo strike
- 54.94
- IV
- 64.8%
- B/E move
- 2.5%
- Pseudo strike
- 59.28
- IV
- 42.3%
- B/E move
- 1.3%
70Δ
- Pseudo strike
- 54.19
- IV
- 64.0%
- B/E move
- 2.0%
- Pseudo strike
- 60.57
- IV
- 45.3%
- B/E move
- 1.1%
75Δ
- Pseudo strike
- 53.45
- IV
- 63.2%
- B/E move
- 1.6%
- Pseudo strike
- 61.85
- IV
- 48.2%
- B/E move
- 0.9%
80Δ
- Pseudo strike
- 52.71
- IV
- 62.3%
- B/E move
- 1.2%
- Pseudo strike
- 63.14
- IV
- 51.1%
- B/E move
- 0.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 37.05% | |
| 34.75% | |
| 37.61% | |
| 37.79% | |
| 36.80% | |
| 36.80% | |
| 37.22% | |
| 36.37% | |
| 36.45% | |
| 41.51% |
Biotechnology
BNTC
Benitec Biopharma Inc., a developing biotechnology company, is focused on the development of new genetic drugs. The company is headquartered in Hayward, California.
More →BNTX
BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.
More →BYSI
BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company is headquartered…
More →CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of T-cell therapies designed for patients with B-cell-mediated autoimmune…
More →CADL
Description unavailable
More →CAI
Description unavailable
More →